Back to GCAE CORE
AZZAZZ Incorporated
Health Care · Industrial Specialties · Mid
$132.36−0.77%
As of 23 Oct 2026Mkt cap $4.1B
Stage 13
WATCH
Fundamentals
50.2/75
Technical
7.9/15
Independent
58.1/90
GCAE viewbusiness is credible but technical recovery is not yet actionable
Price
- 1M
- −4.1%
- 3M
- −11.0%
- 6M
- −7.7%
- 1Y
- +34.3%
Financials & valuation
Cached filing evidence · as of 2026-10-13
Valuation
- P/E
- 23.8xHist median 21.9x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 18.6x
- FCF yield
- 5.4%
Quality
- ROIC
- 10.5%
- Operating margin
- 15.0%
- FCF margin
- 26.9%
- Current ratio
- 1.7x
Growth
- Revenue growth
- +4.6%Latest FY YoY
- Revenue CAGR
- +33.1%
- EPS CAGR
- +33.1%
- FCF CAGR
- +63.4%
Capital
- Share-count trend
- +9.5%3Y annualised
- Net debt
- $538M1.0x OCF
Annual trend
- CAGR 2022–2026
- +33.1%
- Latest · 2026
- $2B
- YoY
- +4.6%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
business is credible but technical recovery is not yet actionable
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2027-01-06
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-13
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded